• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry).

作者信息

Gargiulo Paola, Marzano Federica, Crisci Mario, Marcucci Rossella, Bruzzese Dario, Maloberti Alessandro, Sarullo Filippo Maria, Galasso Gennaro, Indolfi Ciro, Musumeci Giuseppe, Corleto Antonella, Calabrò Paolo, Carugo Stefano, Casu Gavino, Picciolo Amedeo, Ciccone Marco Matteo, Bilato Claudio, Polimeni Alberto, Giallauria Francesco, Catalano Angelo, De Luca Leonardo, Niccoli Giampaolo, Venturini Elio, Pepe Marco, Montisci Roberta, Brunetti Natale Daniele, Patti Giuseppe, Porto Italo, Margonato Alberto, Floresta Marina, Muscoli Saverio, Cameli Matteo, Andò Giuseppe, Di Lorenzo Emilio, Berteotti Martina, Giannattasio Cristina, Sarullo Silvia, Formisano Ciro, Di Costanzo Assunta, Delnevo Fabrizio, Varbella Ferdinando, Cesaro Arturo, Franzese Monica, Mancusi Costantino, Fontanarosa Sara, Di Santo Mariafrancesca, Cotticelli Ciro, Perrone Filardi Fabrizio, Paolillo Stefania, Esposito Giovanni, Corsini Alberto, Perrone Filardi Pasquale

机构信息

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Unit of Interventional Cardiology, AORN dei Colli, Monaldi Hospital, Naples, Italy.

出版信息

J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106. Epub 2024 Dec 11.

DOI:10.1016/j.jacc.2024.10.106
PMID:39665700
Abstract
摘要

相似文献

1
Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry).英克西兰的真实世界疗效与安全性：一项单国家、多中心观察性研究（CHOLINET注册研究）
J Am Coll Cardiol. 2025 Feb 11;85(5):536-540. doi: 10.1016/j.jacc.2024.10.106. Epub 2024 Dec 11.
2
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.在德国的真实世界多中心环境中，依洛尤单抗给药后 LDL-胆固醇降低的个体间变异性很大。
Clin Res Cardiol. 2023 Nov;112(11):1639-1649. doi: 10.1007/s00392-023-02247-8. Epub 2023 Jul 9.
3
"Inclisiran: Early LDL-C target achievement in a real-life population".英克西兰：在现实人群中早期实现低密度脂蛋白胆固醇（LDL-C）目标
Atheroscler Plus. 2025 Jan 28;59:54-58. doi: 10.1016/j.athplu.2025.01.001. eCollection 2025 Mar.
4
First clinical experiences with inclisiran in a real-world setting.inclisiran在真实世界环境中的首次临床经验。
J Clin Lipidol. 2023 Nov-Dec;17(6):818-827. doi: 10.1016/j.jacl.2023.09.005. Epub 2023 Sep 18.
5
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.依洛尤单抗治疗纯合子家族性高胆固醇血症患者的疗效、安全性和耐受性：ORION-5 随机临床试验结果。
Circulation. 2024 Jan 30;149(5):354-362. doi: 10.1161/CIRCULATIONAHA.122.063460. Epub 2023 Oct 18.
6
Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service.降脂治疗中依洛尤单抗的真实世界数据：来自国家医疗服务的初步数据。
J Clin Lipidol. 2024 Sep-Oct;18(5):e809-e816. doi: 10.1016/j.jacl.2024.05.003. Epub 2024 May 24.
7
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.降脂新药 inclisiran 在高心血管风险和高 LDL 胆固醇患者中的长期疗效和安全性（ORION-3）：ORION-1 试验 4 年开放标签扩展的结果。
Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5.
8
A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.一项关于inclisiran治疗高脂血症患者的耐受性、心脏安全性及疗效的系统评价和荟萃分析。
Expert Opin Drug Saf. 2024 Feb;23(2):187-198. doi: 10.1080/14740338.2023.2293201. Epub 2023 Dec 19.
9
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.依洛尤单抗在 LDL 胆固醇升高的高心血管风险患者中的应用。
N Engl J Med. 2017 Apr 13;376(15):1430-1440. doi: 10.1056/NEJMoa1615758. Epub 2017 Mar 17.
10
First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population.在中东人群的真实临床环境中利用inclisiran 治疗高胆固醇血症的首次报告。
Clin Ther. 2024 Mar;46(3):186-193. doi: 10.1016/j.clinthera.2023.12.003. Epub 2024 Jan 14.

引用本文的文献

1
Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study.经皮冠状动脉介入治疗后他汀类药物二级预防治疗中的惰性：一项基于全国人群的队列研究。
BMC Cardiovasc Disord. 2025 Aug 9;25(1):595. doi: 10.1186/s12872-025-05081-0.
2
Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry.inclisiran在意大利威尼托地区的真实世界疗效：INCLIVEN多中心注册研究
Cardiovasc Drugs Ther. 2025 Jul 15. doi: 10.1007/s10557-025-07749-3.
3
Inclisiran: Efficacy in Real World-Systematic Review and Meta-Analysis.
英克西兰：真实世界中的疗效——系统评价与荟萃分析
J Clin Med. 2025 Jun 12;14(12):4163. doi: 10.3390/jcm14124163.